OmniAb Enters Global Collaboration with Eli Lilly to Develop Ion Channel Therapeutics
On August 17, OmniAb (NASDAQ:OABI) announced a global collaboration and license agreement with Eli Lilly (NYSE:LLY) focused on discovering and developing novel ion channel therapeutics. Under the terms of the deal, Lilly gains exclusive commercial rights in exchange for an upfront payment, up to $370 million in development and commercial milestones, plus tiered sales royalties. The partnership highlights a strategic alliance between a micro-cap biotech firm with advanced discovery capabilities and one of healthcare's largest pharmaceutical companies. Financially, Eli Lilly reported strong Q2 2026 performance, generating $23 billion in revenue—up 48% year-over-year—and raising its full-year guidance to $85.0–$87.0 billion. In contrast, OmniAb saw a significant increase in quarterly revenue ($13.4 million) and narrowed its net loss for the same period but remains unprofitable. The deal offers potential upside for both companies: Lilly gains access to innovative discovery platforms without upfront R&D costs while OmniAb receives non-dilutive capital and future royalty opportunities.
Tickers: $LLY